Rubicon Research IPO: The initial public offering (IPO) of Rubicon Research Limited stepped into its final day of public bidding today, October 13. The issue has seen an overall subscription of 13.42 times so far, as per provisional exchange data. The company aims to raise Rs 1377.50 crore from the public offering of 2.84 crore equity shares.
The basis of allotment for the IPO shares is expected to be finalised on October 14, 2025.
Rubicon Research IPO subscription status:
By noon, investors have bid for 22.08 crore shares against the total shares on offer, including major demands from non-institutional and retail investor categories.
Add Zee Business as a Preferred Source
Primarily, Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs) and Retail Individual Investors (RIIs) have booked 2.27 times, 34.14 times, and 15.84 times so far against their allotted portions, respectively.
In terms of shares, the QIB, NII and RII categories have seen subscription of around 2.03 crore, 15.28 crore and 4.72 crore shares against their reserved portion, respectively.
Read More:Â Canara Robeco IPO final day: Should you subscribe? Here’s what Anil Singhvi suggests
Rubicon Research IPO details:
The Rubicon Research IPO is a book-building issue of Rs 1,377.50 crore, including a fresh issue of 1.03 crore equity shares of Rs 500 crore and an offer for sale (OFS) of 1.80 crore equity shares of Rs 877.50 crore.
The company has reserved approximately 36,082 equity shares (based on the upper cap) for its eligible employees.
The company plans to utilise the IPO proceeds for debt repayment, funding inorganic growth and for general corporate purposes.
Price band: Rs 461 to Rs 485 per equity share
Face value: Re 1 each
Subscription date: October 9 to October 13, 2025
Lot size: 30 shares
Minimum investment: Rs 14,550 based on the upper end of the price band
Allotment date: October 14, 2025
Listing date: October 16 on BSE and NSE
Rubicon Research company profile:
Rubicon Research Limited is a pharmaceutical formulations company with a strong presence in regulated markets, particularly the United States.
The company has a portfolio of 66 commercialised products and 72 active ANDAs and NDAs approved by the US FDA.
Financially, it reported a net profit of Rs. 43.30 crore on a total income of Rs. 356.95 crore in Q1 FY26, which ended on June 30, 2025, from a net profit of Rs. 25.57 crore on a total income of Rs. 321.90 crore for the previous period.
